ADC THERAPEUTICS SA's ticker is ADCT and the CUSIP is H0036K147. A total of 61 filers reported holding ADC THERAPEUTICS SA in Q2 2022. The put-call ratio across all filers is 0.74 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,375,936 | -61.6% | 1,533,931 | -8.0% | 0.00% | – |
| Q2 2023 | $3,583,431 | +11.7% | 1,666,712 | +1.3% | 0.00% | – |
| Q1 2023 | $3,207,376 | -47.9% | 1,644,808 | +2.5% | 0.00% | -100.0% |
| Q4 2022 | $6,161,764 | +18572.0% | 1,604,626 | +23287.6% | 0.00% | – |
| Q3 2022 | $33,000 | -34.0% | 6,861 | +8.2% | 0.00% | – |
| Q2 2022 | $50,000 | -55.4% | 6,342 | -16.7% | 0.00% | – |
| Q1 2022 | $112,000 | -94.5% | 7,609 | -92.5% | 0.00% | – |
| Q4 2021 | $2,038,000 | +805.8% | 100,877 | +1121.9% | 0.00% | – |
| Q3 2021 | $225,000 | -6.2% | 8,256 | -16.5% | 0.00% | – |
| Q2 2021 | $240,000 | -29.2% | 9,886 | -28.8% | 0.00% | – |
| Q1 2021 | $339,000 | +340.3% | 13,879 | +474.2% | 0.00% | – |
| Q4 2020 | $77,000 | -40.3% | 2,417 | -38.3% | 0.00% | – |
| Q3 2020 | $129,000 | -21.3% | 3,917 | +11.6% | 0.00% | – |
| Q2 2020 | $164,000 | – | 3,510 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vantage Consulting Group Inc | 1,186,215 | $4,555,066 | 2.69% |
| Blue Owl Capital Holdings LP | 733,568 | $2,816,901 | 1.20% |
| Redmile Group, LLC | 7,590,849 | $29,148,860 | 1.19% |
| AlphaCentric Advisors LLC | 297,500 | $1,142,400 | 1.13% |
| Prosight Management, LP | 463,310 | $1,779,110 | 0.97% |
| GCM Grosvenor Holdings, LLC | 735,471 | $2,824,209 | 0.72% |
| Indie Asset Partners, LLC | 93,839 | $360,342 | 0.40% |
| XTX Topco Ltd | 197,635 | $758,918 | 0.16% |
| Eventide Asset Management | 1,879,959 | $7,219,043 | 0.14% |
| Nantahala Capital Management | 243,290 | $934,234 | 0.06% |